Ken Griffin Verrica Pharmaceuticals Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Verrica Pharmaceuticals Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,900 shares of VRCA stock, worth $78,705. This represents 0.0% of its overall portfolio holdings.

Number of Shares

9,900

Previous 6,100 62.3%

Holding current value

$78,705

Previous $44,000 77.27%

% of portfolio

0.0%

Previous 0.0%

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.89 - $9.56 $134,197 - $217,815	22,784 New	22,784 $166,000
Q3 2023 Nov 14, 2023	SELL	$3.75 - $7.46 $265,286 - $527,742	-70,743 Reduced 80.09%	17,584 $68,000
Q2 2023 Aug 14, 2023	BUY	$5.32 - $6.79 $283,869 - $362,307	53,359 Added 152.59%	88,327 $509,000
Q1 2023 May 15, 2023	SELL	$2.88 - $8.51 $107,945 - $318,963	-37,481 Reduced 51.73%	34,968 $227,000
Q4 2022 Feb 14, 2023	SELL	$2.09 - $3.39 $2,100 - $3,406	-1,005 Reduced 1.37%	72,449 $199,000
Q3 2022 Nov 14, 2022	BUY	$2.17 - $4.3 $69,329 - $137,380	31,949 Added 76.98%	73,454 $215,000

About Verrica Pharmaceuticals Inc.

Ticker VRCA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,094,100
Market Cap $327M
Description
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and w...

More about VRCA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account